Entrada Therapeutics Stock Buy Hold or Sell Recommendation
| TRDA Stock | USD 19.89 0.06 0.30% |
Given the investment horizon of 90 days and your below-average risk tolerance, our recommendation regarding Entrada Therapeutics is 'Strong Sell'. Macroaxis provides Entrada Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TRDA positions.
Check out Entrada Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide. In addition, we conduct extensive research on individual companies such as Entrada and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Entrada |
Execute Entrada Therapeutics Buy or Sell Advice
The Entrada recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Entrada Therapeutics. Macroaxis does not own or have any residual interests in Entrada Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Entrada Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Entrada Therapeutics Trading Alerts and Improvement Suggestions
| The company reported the previous year's revenue of 129.01 M. Net Loss for the year was (6.68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Entrada Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Entrada Therapeutics Is a Great Choice for Trend Investors, Heres Why |
Entrada Therapeutics Returns Distribution Density
The distribution of Entrada Therapeutics' historical returns is an attempt to chart the uncertainty of Entrada Therapeutics' future price movements. The chart of the probability distribution of Entrada Therapeutics daily returns describes the distribution of returns around its average expected value. We use Entrada Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Entrada Therapeutics returns is essential to provide solid investment advice for Entrada Therapeutics.
| Mean Return | 0.35 | Value At Risk | -3.83 | Potential Upside | 6.14 | Standard Deviation | 3.28 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Entrada Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Entrada Stock Institutional Investors
| Shares | Geode Capital Management, Llc | 2024-09-30 | 576.5 K | State Street Corp | 2024-06-30 | 445.2 K | Northern Trust Corp | 2024-09-30 | 247.7 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 201.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 186 K | Millennium Management Llc | 2024-06-30 | 147.3 K | Bank Of New York Mellon Corp | 2024-06-30 | 125.4 K | Nuveen Asset Management, Llc | 2024-06-30 | 122.9 K | Moore Capital Management, Lp | 2024-06-30 | 105 K | Baker Bros Advisors Lp | 2024-09-30 | 4.9 M | Mpm Asset Management, Llc | 2024-09-30 | 4.4 M |
Entrada Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Entrada Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Entrada Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Entrada stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.06 | |
β | Beta against Dow Jones | 2.24 | |
σ | Overall volatility | 2.84 | |
Ir | Information ratio | 0.07 |
Entrada Therapeutics Volatility Alert
Entrada Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Entrada Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Entrada Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Entrada Therapeutics Fundamentals Vs Peers
Comparing Entrada Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Entrada Therapeutics' direct or indirect competition across all of the common fundamentals between Entrada Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Entrada Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Entrada Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Entrada Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Entrada Therapeutics to competition |
| Fundamentals | Entrada Therapeutics | Peer Average |
| Return On Equity | 0.16 | -0.31 |
| Return On Asset | 0.0695 | -0.14 |
| Profit Margin | 0.26 % | (1.27) % |
| Operating Margin | (1.11) % | (5.51) % |
| Current Valuation | 356.25 M | 16.62 B |
| Shares Outstanding | 37.42 M | 571.82 M |
| Shares Owned By Insiders | 12.82 % | 10.09 % |
| Shares Owned By Institutions | 80.80 % | 39.21 % |
| Number Of Shares Shorted | 1.61 M | 4.71 M |
| Price To Book | 1.76 X | 9.51 X |
| Price To Sales | 3.46 X | 11.42 X |
| Revenue | 129.01 M | 9.43 B |
| EBITDA | (321 K) | 3.9 B |
| Net Income | (6.68 M) | 570.98 M |
| Cash And Equivalents | 244.25 M | 2.7 B |
| Cash Per Share | 7.81 X | 5.01 X |
| Total Debt | 68.23 M | 5.32 B |
| Debt To Equity | 0.12 % | 48.70 % |
| Current Ratio | 14.05 X | 2.16 X |
| Book Value Per Share | 11.93 X | 1.93 K |
| Cash Flow From Operations | 139.8 M | 971.22 M |
| Short Ratio | 12.73 X | 4.00 X |
| Earnings Per Share | 1.44 X | 3.12 X |
| Target Price | 25.57 | |
| Number Of Employees | 177 | 18.84 K |
| Beta | -0.26 | -0.15 |
| Market Capitalization | 744.28 M | 19.03 B |
| Total Asset | 469.19 M | 29.47 B |
| Retained Earnings | (194.97 M) | 9.33 B |
| Working Capital | 210.97 M | 1.48 B |
| Net Asset | 469.19 M |
Note: Disposition of 2700 shares by Natarajan Sethuraman of Entrada Therapeutics at 20.0403 subject to Rule 16b-3 [view details]
Entrada Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Entrada . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Entrada Therapeutics Buy or Sell Advice
When is the right time to buy or sell Entrada Therapeutics? Buying financial instruments such as Entrada Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Entrada Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hotels Thematic Idea Now
Hotels
Hotels, inns, motels, and other companies providing lodging and hospitality services. The Hotels theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hotels Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Entrada Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.